Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
Recruiting
Phase 3
Interventional Study
Essential Hypertension
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 19 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 324 (estimated)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(Sacubitril∙Valsartan)
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Participants who are 19 years old or older.
* Participants who have voluntarily decided to participate in this clinical trial and signed ICF.
Exclusion Criteria:
* Participants with a history of secondary hypertension or suspected secondary hypertension.
* Participants with …
Contacts